Cargando…

Drug–Drug Interactions Involving Dexamethasone in Clinical Practice: Myth or Reality?

Concomitant administration of multiple drugs frequently causes severe pharmacokinetic or pharmacodynamic drug–drug interactions (DDIs) resulting in the possibility of enhanced toxicity and/or treatment failure. The activity of cytochrome P450 (CYP) 3A4 and P-glycoprotein (P-gp), a drug efflux pump s...

Descripción completa

Detalles Bibliográficos
Autores principales: Bourdin, Venceslas, Bigot, William, Vanjak, Anthony, Burlacu, Ruxandra, Lopes, Amanda, Champion, Karine, Depond, Audrey, Amador-Borrero, Blanca, Sene, Damien, Comarmond, Chloe, Mouly, Stéphane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10672071/
https://www.ncbi.nlm.nih.gov/pubmed/38002732
http://dx.doi.org/10.3390/jcm12227120
_version_ 1785149487963963392
author Bourdin, Venceslas
Bigot, William
Vanjak, Anthony
Burlacu, Ruxandra
Lopes, Amanda
Champion, Karine
Depond, Audrey
Amador-Borrero, Blanca
Sene, Damien
Comarmond, Chloe
Mouly, Stéphane
author_facet Bourdin, Venceslas
Bigot, William
Vanjak, Anthony
Burlacu, Ruxandra
Lopes, Amanda
Champion, Karine
Depond, Audrey
Amador-Borrero, Blanca
Sene, Damien
Comarmond, Chloe
Mouly, Stéphane
author_sort Bourdin, Venceslas
collection PubMed
description Concomitant administration of multiple drugs frequently causes severe pharmacokinetic or pharmacodynamic drug–drug interactions (DDIs) resulting in the possibility of enhanced toxicity and/or treatment failure. The activity of cytochrome P450 (CYP) 3A4 and P-glycoprotein (P-gp), a drug efflux pump sharing localization and substrate affinities with CYP3A4, is a critical determinant of drug clearance, interindividual variability in drug disposition and clinical efficacy, and appears to be involved in the mechanism of numerous clinically relevant DDIs, including those involving dexamethasone. The recent increase in the use of high doses of dexamethasone during the COVID-19 pandemic have emphasized the need for better knowledge of the clinical significance of drug–drug interactions involving dexamethasone in the clinical setting. We therefore aimed to review the already published evidence for various DDIs involving dexamethasone in vitro in cell culture systems and in vivo in animal models and humans.
format Online
Article
Text
id pubmed-10672071
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-106720712023-11-15 Drug–Drug Interactions Involving Dexamethasone in Clinical Practice: Myth or Reality? Bourdin, Venceslas Bigot, William Vanjak, Anthony Burlacu, Ruxandra Lopes, Amanda Champion, Karine Depond, Audrey Amador-Borrero, Blanca Sene, Damien Comarmond, Chloe Mouly, Stéphane J Clin Med Review Concomitant administration of multiple drugs frequently causes severe pharmacokinetic or pharmacodynamic drug–drug interactions (DDIs) resulting in the possibility of enhanced toxicity and/or treatment failure. The activity of cytochrome P450 (CYP) 3A4 and P-glycoprotein (P-gp), a drug efflux pump sharing localization and substrate affinities with CYP3A4, is a critical determinant of drug clearance, interindividual variability in drug disposition and clinical efficacy, and appears to be involved in the mechanism of numerous clinically relevant DDIs, including those involving dexamethasone. The recent increase in the use of high doses of dexamethasone during the COVID-19 pandemic have emphasized the need for better knowledge of the clinical significance of drug–drug interactions involving dexamethasone in the clinical setting. We therefore aimed to review the already published evidence for various DDIs involving dexamethasone in vitro in cell culture systems and in vivo in animal models and humans. MDPI 2023-11-15 /pmc/articles/PMC10672071/ /pubmed/38002732 http://dx.doi.org/10.3390/jcm12227120 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Bourdin, Venceslas
Bigot, William
Vanjak, Anthony
Burlacu, Ruxandra
Lopes, Amanda
Champion, Karine
Depond, Audrey
Amador-Borrero, Blanca
Sene, Damien
Comarmond, Chloe
Mouly, Stéphane
Drug–Drug Interactions Involving Dexamethasone in Clinical Practice: Myth or Reality?
title Drug–Drug Interactions Involving Dexamethasone in Clinical Practice: Myth or Reality?
title_full Drug–Drug Interactions Involving Dexamethasone in Clinical Practice: Myth or Reality?
title_fullStr Drug–Drug Interactions Involving Dexamethasone in Clinical Practice: Myth or Reality?
title_full_unstemmed Drug–Drug Interactions Involving Dexamethasone in Clinical Practice: Myth or Reality?
title_short Drug–Drug Interactions Involving Dexamethasone in Clinical Practice: Myth or Reality?
title_sort drug–drug interactions involving dexamethasone in clinical practice: myth or reality?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10672071/
https://www.ncbi.nlm.nih.gov/pubmed/38002732
http://dx.doi.org/10.3390/jcm12227120
work_keys_str_mv AT bourdinvenceslas drugdruginteractionsinvolvingdexamethasoneinclinicalpracticemythorreality
AT bigotwilliam drugdruginteractionsinvolvingdexamethasoneinclinicalpracticemythorreality
AT vanjakanthony drugdruginteractionsinvolvingdexamethasoneinclinicalpracticemythorreality
AT burlacuruxandra drugdruginteractionsinvolvingdexamethasoneinclinicalpracticemythorreality
AT lopesamanda drugdruginteractionsinvolvingdexamethasoneinclinicalpracticemythorreality
AT championkarine drugdruginteractionsinvolvingdexamethasoneinclinicalpracticemythorreality
AT depondaudrey drugdruginteractionsinvolvingdexamethasoneinclinicalpracticemythorreality
AT amadorborreroblanca drugdruginteractionsinvolvingdexamethasoneinclinicalpracticemythorreality
AT senedamien drugdruginteractionsinvolvingdexamethasoneinclinicalpracticemythorreality
AT comarmondchloe drugdruginteractionsinvolvingdexamethasoneinclinicalpracticemythorreality
AT moulystephane drugdruginteractionsinvolvingdexamethasoneinclinicalpracticemythorreality